Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study

BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy (RC) is the standard of care for patients with muscle‐invasive bladder cancer (MIBC). However, treatment outcomes are suboptimal. Camrelizumab, a PD‐1 blockade, has shown benefits in several tumors. This study aimed to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sujun, Ji, Zhigang, Jiang, Junhui, Fan, Xinrong, Ma, Qi, Hu, Linjun, Zhang, Wen, Ping, Hao, Wang, Jiansong, Xu, Wanhai, Shi, Benkang, Wang, Wei, Wang, Haifeng, Wang, Honglei, Chen, Shouzhen, Hu, Hailong, Guo, Jianming, Zhang, Shen, Jiang, Shuai, Zhou, Quan, Xing, Nianzeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278497/
https://www.ncbi.nlm.nih.gov/pubmed/37021811
http://dx.doi.org/10.1002/cam4.5900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278497/
https://www.ncbi.nlm.nih.gov/pubmed/37021811
http://dx.doi.org/10.1002/cam4.5900

Ejemplares similares